P John Hamlin
University of Leeds
Quality of lifeInternal medicineSurgeryCross-sectional studyRandomized controlled trialProspective cohort studyImmunologyYoung adultColectomyAzathioprineInfliximabLongitudinal studyInflammatory bowel diseaseIrritable bowel syndromeCalprotectinTolerabilityFaecal calprotectinDepression (differential diagnoses)DiseaseComorbidityCrohn's diseaseMEDLINEAdalimumabTherapeutic drug monitoringUlcerative colitisMoodPopulationMucosal inflammationClinical diseaseConfidence intervalAnxietyThiopurine methyltransferaseMedicineGastroenterologyMeta-analysis
32Publications
12H-index
722Citations
Publications 25
Newest
#1Rebecca SagarH-Index: 5
Last. Christian P. SelingerH-Index: 25
view all 10 authors...
Source
#1Amy HicksH-Index: 1
#2P John Hamlin (University of Leeds)H-Index: 12
Last. Christian P. SelingerH-Index: 25
view all 3 authors...
Background Primary care faecal calprotectin (FC) was introduced in Leeds in 2014 to distinguish inflammatory bowel disease (IBD) from irritable bowel syndrome and with the hope that it may reduce time to IBD diagnosis and treatment. This study examines the association of FC with referral routes, time to diagnosis, and time to treatment. Methods All patients newly referred to IBD clinics in 2013 and 2016 were studied. Data on referral routes and dates, FC, date of first treatment, and proxy outco...
1 CitationsSource
#1Anthony O'ConnorH-Index: 22
#2David J. Gracie (University of Leeds)H-Index: 16
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 4 authors...
Source
#1David J. Gracie (St James's University Hospital)H-Index: 16
#2P John Hamlin (St James's University Hospital)H-Index: 12
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 3 authors...
Summary Brain–gut interactions affect psychological wellbeing and symptom reporting in functional gastrointestinal disorders; the presence of anxiety or depression is associated with the development of new-onset gastrointestinal symptoms, and the presence of gastrointestinal symptoms is associated with the development of psychological disorders de novo. In inflammatory bowel diseases (IBD), the reporting of irritable bowel syndrome (IBS)-type symptoms by patients with quiescent disease is common...
45 CitationsSource
#1Nicholas E Burr (University of Leeds)H-Index: 14
#2Barry Hall (St James's University Hospital)H-Index: 2
Last. Anthony O’Connor (Tallaght Hospital)H-Index: 1
view all 6 authors...
Background and Aims: Surgery is an important treatment for Crohn’s disease (CD) but recurrence occurs in up to 80% of individuals post-operatively. The efficacy of several drugs to prevent post-operative recurrence has been studied in previous meta-analyses, but a number of randomised controlled trials (RCTs) have recently been published. We therefore performed an updated systematic review and network meta-analysis to investigate this issue. Methods: We performed a comprehensive literature searc...
9 CitationsSource
#1Anthony O'Connor (Trinity College, Dublin)H-Index: 22
#2Raguprakash Ratnakumaran (University of Leeds)H-Index: 5
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 9 authors...
Introduction:Fatigue is a frequent, debilitating symptom of inflammatory bowel disease (IBD). Despite this, studies report dissatisfaction among IBD patients regarding how little attention is given to fatigue-related issues during consultations. We performed a pilot randomized controlled trial (RCT) to assess whether a brief, structured, multidisciplinary psychological support program improved fatigue, mood and quality of life indices in patients with quiescent IBD.Methods:The intervention consi...
8 CitationsSource
#1Barry Hall (St James's University Hospital)H-Index: 2
#2P John Hamlin (University of Leeds)H-Index: 12
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 4 authors...
Background and Aims. Mood may have an important role in the natural history of inflammatory bowel disease (IBD). However, the impact of antidepressant use on prognosis is unknown. We aimed to address this in a longitudinal study in a referral population. Methods. We collected demographic data, clinical disease activity and mood using validated questionnaires, and antidepressant use at baseline. Longitudinal disease activity was defined by disease flare or need for glucocorticosteroids, escalatio...
10 CitationsSource
#1Oliver Shutkever (University of Leeds)H-Index: 1
#2David J. Gracie (University of Leeds)H-Index: 16
Last. Philip Quirke (University of Leeds)H-Index: 101
view all 8 authors...
Background: The microbiome is implicated in the pathogenesis of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Whether a distinct microbiome profile is associated with the reporting of IBS-type symptoms in IBD patients is uncertain. We aimed to resolve this issue using a cross-sectional study design. Methods: Using clinical disease activity indices, the Rome III criteria for IBS and fecal calprotectin levels, we divided IBD patients into 4 groups: IBS-type symptoms, quiesce...
10 CitationsSource
#1David J. Gracie (University of Leeds)H-Index: 16
#2Elspeth Guthrie (University of Leeds)H-Index: 40
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 4 authors...
Abstract Background & Aims Inflammatory bowel diseases (IBD) are associated with mood disorders, such as anxiety or depression, but it is not clear whether one contributes to development of the other, or if the interaction is bi-directional (anxiety or depression contributes to the progression of IBD, and IBD affects psychologic health). We performed a 2-year longitudinal prospective study of patients in secondary to care investigate the bi-directionality of IBD and mood disorders. Methods We co...
113 CitationsSource
#1Raguprakash Ratnakumaran (University of Leeds)H-Index: 5
#2N. To (University of Leeds)H-Index: 7
Last. P John Hamlin (University of Leeds)H-Index: 12
view all 11 authors...
AbstractObjectives: Recently, the infliximab biosimilar (CT-P13) received market authorisation for inflammatory bowel disease (IBD), allowing cost benefits when switching to CT-P13. We aim to assess the efficacy and safety of switching from originator infliximab to CT-P13 for new and existing patients.Material and methods: Treatment response, remission, primary and secondary loss of response rates, and adverse events in patients who initiated infliximab originator in the 12 months pre-switch (n ...
20 CitationsSource